Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals has announced that its prostate cancer PET imaging agent, Illuccix, has received marketing authorization in Europe through a decentralized procedure, marking a significant milestone for the company. This approval allows Telix to proceed with the commercial launch of Illuccix across 18 European Economic Area countries, positioning it as a leader in advanced prostate cancer imaging and potentially impacting the standard of care in prostate cancer management.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan, aiming to address significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 8.68%
Average Trading Volume: 3,703
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.2B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.
